Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Unknown 2

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Advanced Solid Tumors 2Advanced Solid Tumor 2Solid Tumors 1Solid Tumor 1MSI-H or dMMR Advanced Solid Tumors 1

Interventions

Injections 26toripalimab 17pembrolizumab 17tislelizumab 12Gemcitabine 8Cisplatin 7spartalizumab 6atezolizumab 6Irinotecan 6Carboplatin 6Paclitaxel 5Oxaliplatin 5Nivolumab 5Leucovorin 5Fluorouracil 5camrelizumab 4Pemetrexed 4Docetaxel 4Cetuximab 4Capecitabine 4trastuzumab deruxtecan 3sintilimab 3olaparib 3lenvatinib 3cediranib 3PM 01183 3Drug Therapy 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumor × anlotinib × Other solid neoplasm × Clear all
NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown
100 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03929965 2019-04-29

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Shanghai Changzheng Hospital

Phase NA Unknown
30 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡